Skip to content

Contact +44 (0) 20 7060 7474 email us

Clinical Trials

Drug Eluting Stent (DES) Clinical Trial Analysis

 

Publication Date July 2009
Publisher Global Markets Direct
Product Type
Pages 92
ISBN Number not applicable
Product Code GMD02887

Price

£660.00
approximately: $999 | €737

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

Global Markets Direct's " Drug Eluting Stent (DES) Clinical Trials Analysis" is an essential source of data and information pertaining to product clinical trials being carried out by Drug Eluting Stent (DES) manufacturers, globally. The report provides exhaustive information on each clinical investigation study with coverage detailed coverage on the pipeline products these trials are being carried out for.

Scope

  • The report provides analysis and review of the key clinical trials being carried out globally and across key Drug Eluting Stent (DES) market categories - Drug Eluting Stent (DES)
  • The report covers information on each product being clinically tested with detailed coverage on the pipeline product profile, the indication it's being investigated for etc.
  • The report provides an in-depth analysis of the clinical trials with information on trial phase, trial 0status, trial acronym, purpose, inclusion and exclusion criteria, description, design, intervention, investigator information, primary and secondary end-points and trial results
  • The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Global Markets Direct's team of industry experts.

Reasons to Buy

  • Effectively plan your Mergers and Acquisitions and partnership strategies by identifying companies with the most promising pipeline.
  • Stay ahead of the information curve in the fast changing Drug Eluting Stent (DES) market.
  • Plan in-licensing and out-licensing opportunities through review of pipeline products and technologies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Proactively plan and execute your competitive strategies by identifying clinical trials status of the leading competitive products in pipeline.
  • Stay ahead of competition by understanding the changing competitive landscape in specific geographies.

Contents

  • 1 List of Tables
  • 1.2 List of Figures
  • 2 Drug Eluting Stent (DES) Clinical Trials
    • 2.1 Drug Eluting Stent (DES) Clinical Trial By Equipment Type
    • 2.2 Drug Eluting Stent (DES) Clinical Trials By Trial Phase and Trial Status
    • 2.3 Drug Eluting Stent (DES) Pipeline Products By Development Stage
    • 2.4 Drug Eluting Stent (DES) Pipeline Products By Therapy Area
    • 2.5 Drug Eluting Stent (DES) Pipeline Products By News Summary
  • 3 Recent Developments
    • 3.1 Product News
      • 3.1.1 Jun 16, 2009: Abbott Announces Enrollment Of First Patient In SPIRIT PRIME Trial Evaluating XIENCE PRIME Everolimus Eluting Coronary Stent System
      • 3.1.2 Jun 04, 2009: XTENT's Custom NX Drug Eluting Stent System Receives Conditional IDE Approval To Begin Two Pivotal Trials
      • 3.1.3 May 29, 2009: Devax Announces Conditional IDE Approval To Commence DIVERGE II Trial Of AXXESS System
      • 3.1.4 May 27, 2009: Boston Scientific Receives FDA Approval For Next-Generation TAXUS Liberte Atom Stent System
      • 3.1.5 May 20, 2009: Treatment Of Complex Coronary Artery Disease With TAXUS Express2 Stent System Found To Be More Cost Effective Than Bypass Surgery In SYNTAX Analysis
      • 3.1.6 May 19, 2009: Cordis Presents Results Of Cypher Sirolimus-Eluting Coronary Stent During Late Breaking Clinical Trials At EuroPCR
      • 3.1.7 May 19, 2009: Cordis' Nevo Sirolimus-Eluting Coronary Stent Shows Superior Results In Comparison To Taxus Liberte Stent
      • 3.1.8 May 15, 2009: Medtronic Presents New data Of Endeavor Stent's Long-Term Safety And Efficacy At Interventional Cardiology Congress
      • 3.1.9 May 14, 2009: Medtronic Announces The Completion Of Enrollment In RESOLUTE International Trial
      • 3.1.10 May 12, 2009: Johnson & Johnson (JNJ) To Host A Conference Call For Financial Analysts To Review Trial Results From NEVO RES I
      • 3.1.11 May 11, 2009: Boston Scientific Welcomes Publication Of Data From The Swedish National Registry
      • 3.1.12 Mar 30, 2009: Medtronic Receives Regulatory Approval For Endeavor Drug-Eluting Coronary Stent In Japan
      • 3.1.13 Mar 29, 2009: Abbott's XIENCE V Shows Increasing Clinical Advantages Over TAXUS Express2/TAXUS Liberte Between Two And Three Years
      • 3.1.14 Mar 28, 2009: Medtronic's Endeavor Stent Shows Consistent And Sustained Safety And Effectiveness Benefits At Two Years
      • 3.1.15 Mar 24, 2009: Abbott Commences The Next Phase Of Clinical Trial Of Its Fully Bioabsorbable Drug Eluting Coronary Stent System
      • 3.1.16 Mar 16, 2009: Cordis Announces NEVO II Clinical Trial Comparing The Nevo Sirolimus-Eluting Coronary Stent To The Xience Stent
      • 3.1.17 Mar 16, 2009: Cordis Announces NEVO II Clinical Trial Comparing The Nevo Sirolimus-Eluting Coronary Stent To The Xience Stent
      • 3.1.18 Mar 12, 2009: Abbott Announces Publication Of Two-Year Results Of Fully Bioabsorbable Drug Eluting Stent
      • 3.1.19 Mar 04, 2009: Micell Technologies To Showcase Its Rapid Absorption Polymer DES System At CRT 2009
      • 3.1.20 Feb 05, 2009: Final Modules Of Boston Scientific's Second-Generation Small Vessel And Long Lesion Stents Submitted To FDA
      • 3.1.21 Feb 02, 2009: Medtronic Announces The Completion Of Patient Enrollment In Global Head-To-Head Stent-Safety Study
      • 3.1.22 Jan 28, 2009: TAXUS Liberte Drug-Eluting Stent System Of Boston Scientific Gains Japanese Approval
      • 3.1.23 Jan 26, 2009: Pivotal Two Year Results On XIENCE V Drug Eluting Stent Data Published
      • 3.1.24 Jan 22, 2009: Isotechnika Announces Enrollment Completion Of Its Partner Atrium's CONFIRM 1 Trial For Voclosporin Coated Coronary Stent System
      • 3.1.25 Nov 12, 2008: Medtronic Launches Endeavor Sprint Drug-Eluting Stent System On Rapid Exchange In United States
      • 3.1.26 Nov 07, 2008: Interim Analysis Of Data From e-HEALING Registry Of OrbusNeich's Genous Bio-Engineered R Stent To Be Presented At AHA Scientific Sessions 2008
      • 3.1.27 Oct 28, 2008: Abbott's XIENCE V Drug Eluting Stent Wins Prestigious Chicago Innovation Award
      • 3.1.28 Oct 28, 2008: New Cappella Heart Stent Shows Promise
      • 3.1.29 Oct 21, 2008: MIV's VESTASYNC I Trial Preliminary Results Published
      • 3.1.30 Oct 16, 2008: Danish Study Supports Efficacy Of Endeavor Stent
      • 3.1.31 Oct 16, 2008: Elixir Medical Corporation Announced Positive First-In-Man Results Of Novolimus Drug Eluting Coronary Stent System
      • 3.1.32 Oct 16, 2008: OPEN I Study Demonstrates Safety Of The Stentys Stent At 30-Day Follow-Up Of 40 Patients
      • 3.1.33 Oct 15, 2008: HORIZONS AMI Trial Demonstrates Superior Outcomes With TAXUS Drug-Eluting Stents In Heart Attack Patients
      • 3.1.34 Oct 14, 2008: Endeavor vs. Taxus: Medtronic's Drug-Eluting Coronary Stent Linked To Fewer Heart Attacks At Two Years Post Implant
      • 3.1.35 Oct 14, 2008: Interim Analysis Of 12-Month Data From e-HEALING Registry Shows Good Safety And Efficacy In Real-World Use Of OrbusNeich's Genous Bio-engineered R stent
      • 3.1.36 Oct 13, 2008: 12-Month ATLANTA Trial Data Show Sustained Benefit Of Catania Stent In Treatment Of De Novo Coronary Lesions
      • 3.1.37 Oct 13, 2008: Abbott's XIENCE V Drug Eluting Stent Outperforms TAXUS In Key Efficacy And Safety Endpoints Out To Two Years
      • 3.1.38 Oct 13, 2008: Custom NX Drug Eluting Stent System Continues To Demonstrate Favorable Outcomes In Challenging Patient Populations At One, Two And Three Years
      • 3.1.39 Oct 13, 2008: New Data Shows Abbott's Bioabsorbable Drug Eluting Stent Is Absorbed Within Two Years - Leaving Behind Functioning Blood Vessels
      • 3.1.40 Oct 12, 2008: Medtronic's Third-Generation Endeavor Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile
      • 3.1.41 Oct 12, 2008: New Data On Medtronic's Endeavor Drug-Eluting Coronary Stent Shows Strong Performance In Complex Patients And Durable Efficacy
      • 3.1.42 Oct 12, 2008: TAXUS Express Stent Shows Similarly Low Re-Intervention Rates In Patients With Diabetes Compared To Non-Diabetics In Arrive Registry Program
      • 3.1.43 Oct 10, 2008: Boston Scientific Announces FDA Approval of Second-Generation TAXUS Liberte Drug-Eluting Stent
      • 3.1.44 Oct 10, 2008: Cappella To Present Critical Data From Coronary Bifurcation Stent Studies At TCT 2008
      • 3.1.45 Oct 10, 2008: XTENT Announces Clinical Trial Data To Be Presented At Annual Meeting Of Transcatheter Cardiovascular Therapeutics Next Week
      • 3.1.46 Oct 06, 2008: Data From Multiple Clinical Trials Of OrbusNeich's Genous Bio-engineered R stent To Be Presented At TCT 2008
      • 3.1.47 Sep 25, 2008: Boston Scientific Corporation Announces FDA Approval Of TAXUS Express2 Atom Stent System
      • 3.1.48 Sep 25, 2008: Boston Scientific Corporation Announces FDA Approval Of TAXUS Express2 Paclitaxel-Eluting Coronary Stent System For The Treatment Of In-Stent Restenosis
      • 3.1.49 Sep 22, 2008: Sorin Group Announces First Patient Enrolment In The E-Optima Registry
      • 3.1.50 Sep 01, 2008: Biosensors DES Demonstrates Equivalent Safety And Efficacy To Industry Leading DES In First 'Real World, All Comers' Clinical Study
      • 3.1.51 Sep 01, 2008: SYNTAX Trial Reports Comparable Safety Outcomes For Patients Treated With TAXUS Express2 Stents Or Bypass Surgery
      • 3.1.52 Aug 26, 2008: Boston Scientific Corporation To Present Data From Landmark SYNTAX Clinical Trial
      • 3.1.53 Aug 14, 2008: Boston Scientific Shares Falls On Next-Generation Taxus Liberte Stent Questions
      • 3.1.54 Aug 09, 2008: Positive Results For Bioabsorbable Therapeutics Salix Drug-Eluting Stent Coating
      • 3.1.55 Aug 05, 2008: MIV Therapeutics Announces Excellent Safety And Efficacy Of VESTAsync Polymer-Free Drug-Eluting Stent At 12-Month Clinical Follow Up
      • 3.1.56 Jul 09, 2008: Abbott Begins Post-Approval Study Of XIENCE V Drug Eluting Stent
      • 3.1.57 May 13, 2008: PAINT Trial Results Support Safety And Efficacy Of The Infinnium And Supralimus Stents
      • 3.1.58 Apr 01, 2008: Disappointing Resuts For Pimecrolimus, Investigational Anti-restenosis Drug
      • 3.1.59 Mar 29, 2008: TAXUS Express Stent Shows Similarly Low Re-intervention Rates In Diabetic Patients Compared To Non-Diabetics In ARRIVE 1 And 2 Registries
      • 3.1.60 Feb 18, 2008: First Live Implants Of BioMatrix Drug-Eluting Stent In Europe Following CE Mark Approval
      • 3.1.61 Oct 22, 2007: Abbott Announces Positive One-Year Results From The World's First Clinical Trial Of A Fully Bioabsorbable Drug Eluting Coronary Stent
      • 3.1.62 Oct 22, 2007: Boston Scientific's Next-Generation Stent Shows Improved Clinical Outcomes In Complex Lesions
      • 3.1.63 Sep 05, 2007: TAXUS WOMAN Study Reports Positive Clinical Outcomes For The TAXUS Drug-Eluting Stent In Women
      • 3.1.64 Mar 24, 2007: Abbott Announces Positive Six-Month Results From ABSORB Clinical Trial
      • 3.1.65 Feb 14, 2007: Biosensors Announces Positive Results In Ongoing Studies Of The BioMatrix Freedom Stent
      • 3.1.66 Feb 14, 2007: Biosensors Announces Positive Results In Ongoing Studies Of The BioMatrix Stent
    • 3.2 Product Approvals
      • 3.2.1 May 27, 2009: Boston Scientific Receives FDA Approval For Next-Generation TAXUS Liberte Atom Stent System
      • 3.2.2 Mar 30, 2009: Medtronic Receives Regulatory Approval For Endeavor Drug-Eluting Coronary Stent In Japan
      • 3.2.3 Jan 28, 2009: TAXUS Liberte Drug-Eluting Stent System Of Boston Scientific Gains Japanese Approval
      • 3.2.4 Oct 10, 2008: Boston Scientific Announces FDA Approval of Second-Generation TAXUS Liberte Drug-Eluting Stent
      • 3.2.5 Sep 25, 2008: Boston Scientific Corporation Announces FDA Approval Of TAXUS Express2 Atom Stent System
      • 3.2.6 Sep 25, 2008: Boston Scientific Corporation Announces FDA Approval Of TAXUS Express2 Paclitaxel-Eluting Coronary Stent System For The Treatment Of In-Stent Restenosis
    • 3.3 Clinical Trials
      • 3.3.1 Jun 16, 2009: Abbott Announces Enrollment Of First Patient In SPIRIT PRIME Trial Evaluating XIENCE PRIME Everolimus Eluting Coronary Stent System
      • 3.3.2 Jun 04, 2009: XTENT's Custom NX Drug Eluting Stent System Receives Conditional IDE Approval To Begin Two Pivotal Trials
      • 3.3.3 May 29, 2009: Devax Announces Conditional IDE Approval To Commence DIVERGE II Trial Of AXXESS System
      • 3.3.4 May 20, 2009: Treatment Of Complex Coronary Artery Disease With TAXUS Express2 Stent System Found To Be More Cost Effective Than Bypass Surgery In SYNTAX Analysis
      • 3.3.5 May 19, 2009: Cordis' Nevo Sirolimus-Eluting Coronary Stent Shows Superior Results In Comparison To Taxus Liberte Stent
      • 3.3.6 May 19, 2009: Cordis Presents Results Of Cypher Sirolimus-Eluting Coronary Stent During Late Breaking Clinical Trials At EuroPCR
      • 3.3.7 May 15, 2009: Medtronic Presents New data Of Endeavor Stent's Long-Term Safety And Efficacy At Interventional Cardiology Congress
      • 3.3.8 May 12, 2009: Johnson & Johnson (JNJ) To Host A Conference Call For Financial Analysts To Review Trial Results From NEVO RES I
      • 3.3.9 May 11, 2009: Boston Scientific Welcomes Publication Of Data From The Swedish National Registry
      • 3.3.10 Mar 29, 2009: Abbott's XIENCE V Shows Increasing Clinical Advantages Over TAXUS Express2/TAXUS Liberte Between Two And Three Years
      • 3.3.11 Mar 28, 2009: Medtronic's Endeavor Stent Shows Consistent And Sustained Safety And Effectiveness Benefits At Two Years
      • 3.3.12 Mar 24, 2009: Abbott Commences The Next Phase Of Clinical Trial Of Its Fully Bioabsorbable Drug Eluting Coronary Stent System
      • 3.3.13 Mar 16, 2009: Cordis Announces NEVO II Clinical Trial Comparing The Nevo Sirolimus-Eluting Coronary Stent To The Xience Stent
      • 3.3.14 Mar 16, 2009: Cordis Announces NEVO II Clinical Trial Comparing The Nevo Sirolimus-Eluting Coronary Stent To The Xience Stent
      • 3.3.15 Mar 12, 2009: Abbott Announces Publication Of Two-Year Results Of Fully Bioabsorbable Drug Eluting Stent
      • 3.3.16 Feb 02, 2009: Medtronic Announces The Completion Of Patient Enrollment In Global Head-To-Head Stent-Safety Study
      • 3.3.17 Jan 26, 2009: Pivotal Two Year Results On XIENCE V Drug Eluting Stent Data Published
      • 3.3.18 Jan 22, 2009: Isotechnika Announces Enrollment Completion Of Its Partner Atrium's CONFIRM 1 Trial For Voclosporin Coated Coronary Stent System
      • 3.3.19 Nov 07, 2008: Interim Analysis Of Data From e-HEALING Registry Of OrbusNeich's Genous Bio-Engineered R Stent To Be Presented At AHA Scientific Sessions 2008
      • 3.3.20 Oct 28, 2008: New Cappella Heart Stent Shows Promise
      • 3.3.21 Oct 21, 2008: MIV's VESTASYNC I Trial Preliminary Results Published
      • 3.3.22 Oct 16, 2008: Elixir Medical Corporation Announced Positive First-In-Man Results Of Novolimus Drug Eluting Coronary Stent System
      • 3.3.23 Oct 16, 2008: Danish Study Supports Efficacy Of Endeavor Stent
      • 3.3.24 Oct 16, 2008: OPEN I Study Demonstrates Safety Of The Stentys Stent At 30-Day Follow-Up Of 40 Patients
      • 3.3.25 Oct 15, 2008: HORIZONS AMI Trial Demonstrates Superior Outcomes With TAXUS Drug-Eluting Stents In Heart Attack Patients
      • 3.3.26 Oct 14, 2008: Endeavor vs. Taxus: Medtronic's Drug-Eluting Coronary Stent Linked To Fewer Heart Attacks At Two Years Post Implant
      • 3.3.27 Oct 14, 2008: Interim Analysis Of 12-Month Data From e-HEALING Registry Shows Good Safety And Efficacy In Real-World Use Of OrbusNeich's Genous Bio-engineered R stent
      • 3.3.28 Oct 13, 2008: New Data Shows Abbott's Bioabsorbable Drug Eluting Stent Is Absorbed Within Two Years - Leaving Behind Functioning Blood Vessels
      • 3.3.29 Oct 13, 2008: Custom NX Drug Eluting Stent System Continues To Demonstrate Favorable Outcomes In Challenging Patient Populations At One, Two And Three Years
      • 3.3.30 Oct 13, 2008: Abbott's XIENCE V Drug Eluting Stent Outperforms TAXUS In Key Efficacy And Safety Endpoints Out To Two Years
      • 3.3.31 Oct 13, 2008: 12-Month ATLANTA Trial Data Show Sustained Benefit Of Catania Stent In Treatment Of De Novo Coronary Lesions
      • 3.3.32 Oct 12, 2008: TAXUS Express Stent Shows Similarly Low Re-Intervention Rates In Patients With Diabetes Compared To Non-Diabetics In Arrive Registry Program
      • 3.3.33 Oct 12, 2008: Medtronic's Third-Generation Endeavor Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile
      • 3.3.34 Oct 10, 2008: Cappella To Present Critical Data From Coronary Bifurcation Stent Studies At TCT 2008
      • 3.3.35 Oct 10, 2008: XTENT Announces Clinical Trial Data To Be Presented At Annual Meeting Of Transcatheter Cardiovascular Therapeutics Next Week
      • 3.3.36 Oct 06, 2008: Data From Multiple Clinical Trials Of OrbusNeich's Genous Bio-engineered R stent To Be Presented At TCT 2008
      • 3.3.37 Sep 22, 2008: Sorin Group Announces First Patient Enrolment In The E-Optima Registry
      • 3.3.38 Sep 01, 2008: Biosensors DES Demonstrates Equivalent Safety And Efficacy To Industry Leading DES In First 'Real World, All Comers' Clinical Study
      • 3.3.39 Sep 01, 2008: SYNTAX Trial Reports Comparable Safety Outcomes For Patients Treated With TAXUS Express2 Stents Or Bypass Surgery
      • 3.3.40 Aug 26, 2008: Boston Scientific Corporation To Present Data From Landmark SYNTAX Clinical Trial
      • 3.3.41 Aug 05, 2008: MIV Therapeutics Announces Excellent Safety And Efficacy Of VESTAsync Polymer-Free Drug-Eluting Stent At 12-Month Clinical Follow Up
      • 3.3.42 Jul 09, 2008: Abbott Begins Post-Approval Study Of XIENCE V Drug Eluting Stent
  • 4 Appendix
    • 4.1 Methodology
      • 4.1.1 Coverage
      • 4.1.2 Secondary Research
      • 4.1.3 Primary Research
      • 4.1.4 Expert Panel Validation
    • 4.2 Contact Us
    • 4.3 About Global Markets Direct
    • 4.4 Disclaimer
  • 1 List of Tables
    • Table 1: Drug Eluting Stent (DES) Clinical Trial By Equipment Type
    • Table 2: Drug Eluting Stent (DES) Clinical Trials By Trial Phase and Trial Status
    • Table 3: Drug Eluting Stent (DES) Pipeline Products By Development Stage
    • Table 4: Drug Eluting Stent (DES) Pipeline Products By Therapy Area
    • Table 5: Drug Eluting Stent (DES) Pipeline Products By News Summary
  • 1.2 List of Figures
    • Figure 1: Global Markets Direct Methodology